Chemed (CHE)
(Delayed Data from NYSE)
$558.27 USD
+3.55 (0.64%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $559.16 +0.89 (0.16%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$558.27 USD
+3.55 (0.64%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $559.16 +0.89 (0.16%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Zacks News
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.
Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.
Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.
Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.
Outpatient & Home Healthcare Stock Outlook: Prospects Bright
by Zacks Equity Research
The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.
Outpatient Market Gains on Social Awareness: 3 Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.
LHCG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LHCG vs. CHE: Which Stock Is the Better Value Option?
Walgreens Boots' Retail Pharmacy Strong Despite Several Woes
by Zacks Equity Research
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
New Strong Buy Stocks for June 18th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
LHCG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LHCG vs. CHE: Which Stock Is the Better Value Option?
Envision Healthcare's (EVHC) Ratings on Review for Downgrade
by Zacks Equity Research
Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.
The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oshkosh, Chemed and Urban Outfitters
The World Cup Begins: Global Week Ahead
by John Blank
We have lots of global events this week, counted in terms of soccer games, a historic diplomatic summit, and three major monetary policy meetings.
Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.
LHCG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LHCG vs. CHE: Which Stock Is the Better Value Option?
Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Why Is Chemed (CHE) Up 13.6% Since Its Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why
by Zacks Equity Research
Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.
BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.
STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.